zurück

Pembrolizumab (new indication: renal cell carcinoma, adjuvant therapy, pretreated patients)

 

Subject:

  • Active Sustance: Pembrolizumab
  • Name: Keytruda®
  • Therapeutic area: Renal cell carcinoma
  • Pharmaceutical company: MSD Sharp & Dohme GmbH

 

Time table:

  • Start: 01.08.2022
  • Publication of assessment: 01.11.2022
  • End of public hearing: 22.11.2022
  • Final decision by G-BA: middle of January 2023

 

Comparative therapy:

  • Watchful waiting